Fetal tachycardia is treated primarily by giving the mother heart-rhythm medications that cross the placenta and slow the baby’s heart rate. A fetal heart rate above 160 beats per minute sustained for more than five minutes is the standard threshold for diagnosis, though most cases that require active treatment involve rates well above 180 bpm. The specific treatment approach depends on the type of abnormal rhythm, how far along the pregnancy is, and whether the baby is showing signs of heart failure.
How Fetal Tachycardia Is Diagnosed
Fetal tachycardia is usually first noticed during a routine prenatal visit when the baby’s heart rate is higher than expected. A normal fetal heart rate ranges from about 110 to 160 bpm. If the rate is consistently above 160, further testing is needed to determine what type of fast rhythm is occurring.
The two most common types are supraventricular tachycardia (SVT), where the heart beats extremely fast (often 220 to 300 bpm) due to an abnormal electrical circuit, and atrial flutter, where the upper chambers of the heart beat in a rapid, organized pattern. Distinguishing between these matters because they respond differently to medication. A fetal echocardiogram, which uses ultrasound to study the heart’s structure and rhythm in detail, is the key tool for making this distinction.
Transplacental Medication: The Standard Approach
Because the baby is still in the womb, the most practical way to deliver medication is through the mother’s bloodstream. The drug crosses the placenta and reaches the baby’s circulation. This is called transplacental therapy, and it is the cornerstone of treatment for fetal tachycardia diagnosed before the baby is mature enough for delivery.
The first medication tried in most cases is digoxin, a drug that slows electrical conduction in the heart. The mother receives an initial loading phase, typically given intravenously over the first 24 hours, followed by a daily oral maintenance dose. Pregnant women clear digoxin from their bodies faster than non-pregnant individuals, so doses often need to be adjusted upward. Blood levels are monitored, though research from a 2016 study in PubMed Central noted that standard maternal blood levels don’t always reliably reflect how much drug is reaching the fetus.
Digoxin alone converts the rhythm in roughly half of cases. When it doesn’t work, a second medication is added. The combination of digoxin with flecainide (a stronger rhythm-stabilizing drug) has proven highly effective. In one series from a tertiary perinatal cardiac center, this combination restored a normal heart rate in 17 out of 18 cases, a 94.5% success rate, with conversion happening at a median of three days. Another option is sotalol, a medication that works through a different mechanism and is sometimes preferred for certain types of SVT.
What Monitoring Looks Like for the Mother
These medications are powerful, and they affect the mother’s heart too. Throughout treatment, the mother undergoes regular heart tracings (ECGs) to watch for signs of drug toxicity. Each medication has its own warning signs. Digoxin can cause characteristic changes in the electrical pattern of the heart, including specific alterations in the ST segment and T wave. Flecainide and sotalol can both dangerously prolong a measurement called the QTc interval, which reflects how long it takes the heart to reset between beats. If this interval stretches beyond 0.48 seconds, the medication is typically stopped or reduced.
Blood work is also part of the monitoring process. Electrolyte imbalances, particularly low potassium or magnesium, can amplify drug side effects and need to be corrected quickly. The mother may need to be admitted to the hospital during the loading phase and for the first several days of treatment, with outpatient follow-up once her levels stabilize and the baby’s heart rate responds.
When the Baby Develops Heart Failure
The biggest concern with sustained fetal tachycardia is the development of hydrops fetalis, a condition where fluid accumulates abnormally around the baby’s organs (in the skin, abdomen, or around the heart and lungs). This happens because a heart beating too fast for too long eventually starts to fail as a pump. Hydrops is a serious complication that changes the urgency and intensity of treatment.
Even with hydrops, transplacental medication remains the primary strategy. Digoxin actually has an advantage here because, beyond slowing the heart rate, it strengthens the heart’s contractions, which can help a failing fetal heart recover. A case report in the Turkish Journal of Obstetrics and Gynecology described successful treatment of a hydropic fetus using a combination of sotalol and digoxin given to the mother. The key message from the literature is clear: the presence of hydrops is not a reason to stop treatment. Instead, it’s a reason to escalate it.
That said, hydrops does reduce overall treatment success rates and is considered a risk factor for the baby needing continued heart rhythm treatment after birth.
Direct Fetal Treatment in Rare Cases
When transplacental therapy fails, a more invasive option exists: delivering medication directly to the baby through the umbilical vein. This procedure, performed under continuous ultrasound guidance, uses a needle to access the umbilical cord (a technique called cordocentesis) and inject a fast-acting drug.
Adenosine is the drug most commonly used this way. It works almost instantly to interrupt the abnormal electrical circuit causing SVT, but it breaks down in the bloodstream within seconds. That ultrashort duration is exactly why it can’t be given to the mother and expected to reach the baby. In one published case, two small doses of adenosine injected directly into the umbilical vein, spaced one to two minutes apart, were enough to restore a normal rhythm of 115 bpm. The dose is calculated based on the baby’s estimated weight from ultrasound measurements.
This approach is reserved for situations where oral medications have failed and the baby is too premature for safe delivery. It carries procedural risks, including preterm labor and bleeding, so it’s performed only at specialized centers.
Gestational Age and Delivery Decisions
How far along the pregnancy is plays a central role in every treatment decision. In the preterm period, the goal is to control the rhythm medically and avoid adding the risks of prematurity on top of the complications of tachycardia. Treatment is considered refractory when there’s no improvement, or the baby’s condition worsens, despite the mother reaching adequate drug levels.
At or near term (generally 37 weeks and beyond), the calculus shifts. A short trial of medication may still be attempted, but if the rhythm doesn’t convert quickly, delivery becomes a reasonable option because the baby can be treated directly after birth with more precise dosing and monitoring. For babies between viability and term, the decision is more nuanced and depends on fetal weight, overall condition, and whether hydrops is present or worsening.
Mirror syndrome, a rare complication where the mother develops swelling and high blood pressure that mirrors the baby’s hydrops, is another scenario where delivery may be necessary regardless of gestational age, because the mother’s health is now at risk too.
What Happens After Birth
Many babies who had fetal tachycardia that responded to treatment do well after delivery and may not need ongoing medication. However, some will experience recurrent fast heart rhythms in the newborn period, particularly those who had hydrops or whose arrhythmia was difficult to control in utero. These babies are typically monitored in a neonatal intensive care unit and may be started on oral anti-arrhythmic medication for the first several months of life.
Most forms of SVT in infants resolve on their own during the first year as the heart’s electrical system matures. Atrial flutter that appears only during fetal life rarely recurs after birth. Long-term outcomes for babies whose tachycardia was successfully treated before delivery are generally favorable, especially when treatment began before the onset of hydrops.